Contents lists available at ScienceDirect



Free Radical Biology & Medicine



journal homepage: www.elsevier.com/locate/freeradbiomed

#### Original Contribution

# Vitamin B<sub>12</sub> protects against superoxide-induced cell injury in human aortic endothelial cells

### Edward S. Moreira <sup>a,b,c,1</sup>, Nicola E. Brasch <sup>b,c</sup>, June Yun <sup>a,c,\*</sup>

<sup>a</sup> Integrative Medical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272, USA

<sup>b</sup> Department of Chemistry, Kent State University, Kent, OH 44242, USA

<sup>c</sup> School of Biomedical Sciences, Kent State University, Kent, OH 44242, USA

#### ARTICLE INFO

Article history: Received 10 January 2011 Revised 2 May 2011 Accepted 25 May 2011 Available online 2 June 2011

Keywords: Superoxide Homocysteine Cobalamin Apoptosis Oxidative stress Vascular endothelium Antioxidant Free radicals

#### ABSTRACT

Superoxide  $(O_2^{--})$  is implicated in inflammatory states including arteriosclerosis and ischemia–reperfusion injury. Cobalamin (Cbl) supplementation is beneficial for treating many inflammatory diseases and also provides protection in oxidative-stress-associated pathologies. Reduced Cbl reacts with  $O_2^{--}$  at rates approaching that of superoxide dismutase (SOD), suggesting a plausible mechanism for its anti-inflammatory properties. Elevated homocysteine (Hcy) is an independent risk factor for cardiovascular disease and endothelial dysfunction. Hcy increases  $O_2^{--}$  levels in human aortic endothelial cells (HAEC). Here, we explore the protective effects of Cbl in HAEC exposed to various  $O_2^{--}$ sources, including increased Hcy levels. Hcy increased  $O_2^{--}$  levels (1.6-fold) in HAEC, concomitant with a 20% reduction in cell viability and a 1.5-fold increase in apoptotic death. Pretreatment of HAEC with physiologically relevant concentrations of cyanocobalamin (CNCbl) (10–50 nM) prevented Hcy-induced increases in  $O_2^{--}$  and cell death. CNCbl inhibited both Hcy and rotenone-induced mitochondrial  $O_2^{--}$  production. Similarly, HAEC challenged with paraquat showed a 1.5-fold increase in  $O_2^{--}$  levels and a 30% decrease in cell viability, both of which were prevented with CNCbl pretreatment. CNCbl also attenuated elevated  $O_2^{--}$  levels after exposure of cells to a Cu/Zn-SOD inhibitor. Our data suggest that Cbl acts as an efficient intracellular  $O_2^{--}$  scavenger.

© 2011 Elsevier Inc. All rights reserved.

Cobalamins (Cbl; vitamin B<sub>12</sub> derivatives) are micronutrients essential for the synthesis of methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl), the respective cofactors for cytosolic methionine synthase (MS) and mitochondrial L-methylmalonyl-CoA mutase. Reduced Cbl cofactors in the catalytic cycles are sensitive to oxidation [1,2]; hence, both MS and L-methylmalonyl-CoA mutase are inactivated by reactive oxygen species (ROS). MS plays a key role in the metabolism of homocysteine (L-Hcv. Hcv), a by-product of methylation reactions that is metabolized to cysteine or methionine. In endothelial cells, Hcy metabolism depends exclusively on Cbldependent MS [3]. Impaired MS activity due to Cbl deficiency results in elevated Hcy, a risk factor for cardiovascular disease [4]. Hcy also elevates  $O_2^{\bullet-}$  levels, leading to increased oxidative stress, which further hinders Cbl's metabolism. Importantly, Cbl exhibits antioxidant effects in Hcy-independent systems [5,6]. Birch et al. reported that Cbl protects against hydrogen peroxide-induced oxidative stress [5], and our preliminary experiments demonstrated the potential of Cbl to attenuate elevated  $O_2^{\bullet-}$  levels [6].

Cbl deficiency is a common and significant public health problem, particularly among the elderly [4]. Up to 40% of the elderly U.S. population is  $B_{12}$  deficient [7]. After folate fortification in food, Cbl deficiency became the primary modifiable cause of hyperhomocysteinemia [8]. Vitamin supplements containing cyanocobalamin (CNCbl, vitamin  $B_{12}$ ) decrease low-density lipoprotein oxidation in both healthy individuals and patients with coronary artery disease [9]. Cbl supplementation is also beneficial in treating many inflammatory diseases, and there is accumulating evidence that Cbl can protect against oxidative stress-associated pathologies [10–16]. Levels of the Cbl transport protein transcobalamin increase during inflammation [17,18], concomitant with NF- $\kappa$ B activation induced by various stimuli, including ROS. Taken together, these studies suggest a potential role for Cbl in the regulation of inflammatory processes [15,19].

Recently we demonstrated that the reduced form of Cbl, cob(II) alamin (Cbl(II)) reacts with  $O_2^{--}$  with a second-order rate constant of  $7 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$ , close to that observed for superoxide dismutase itself (Cu/Zn-SOD;  $k = 2 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$ ) [6]. Given that Cbl(II) is a major intracellular Cbl form [2], we hypothesized that scavenging of  $O_2^{--}$  by Cbl is an important mechanism by which Cbl can protect cells against oxidative stress.

 $O_2^{--}$  is a free radical product of a one-electron reduction of oxygen. It is produced by mitochondrial and reticular membrane electron transport systems, or enzymes including NADPH oxidase and

<sup>\*</sup> Corresponding author at: Integrative Medical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272, USA. *E-mail address*: jyun@neoucom.edu (J. Yun).

<sup>&</sup>lt;sup>1</sup> Present address: Division of Vascular Surgery, Department of Surgery, Northwestern University, Chicago, IL, USA.

<sup>0891-5849/\$ –</sup> see front matter © 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.freeradbiomed.2011.05.034

xanthine oxidase and uncoupled nitric oxide synthase [20]. Exposing cells to Hcy also results in elevated levels of  $O_2^{\bullet-}[21,22]$ .  $O_2^{\bullet-}$  is involved in both physiological and pathological processes [23], with  $O_2^{\bullet-}$  overproduction implicated in a range of inflammatory states such as rheumatoid arthritis, osteoarthritis, arteriosclerosis, and ischemiareperfusion [24]. The toxicity of increased  $O_2^{*-}$  levels is evident in homozygous SOD2 knockout mice, which die within the first 3 weeks of age [25].  $O_2^{*-}$  can inactivate a range of enzymes in addition to causing direct molecular damage by initiating lipoperoxidation, leading to the destruction of neurotransmitters and hormones, and DNA single-strand damage [20]. Moreover,  $0_2^{\bullet-}$  can generate peroxynitrite via its reaction with nitric oxide and hydrogen peroxide via dismutation. From these species, stronger damaging oxidants can be generated, such as the carbonate, hydroxyl and nitrogen dioxide radicals, and oxoferryl complexes [26]. Therefore a tight control of  $O_2^{\bullet-}$ levels is paramount to prevent the formation of secondary oxidants.

In this work we describe the protective effects of physiologically relevant concentrations of CNCbl against elevated intracellular  $O_2^{-1}$  levels induced by paraquat and L-Hcy and the associated cell injury in primary human aortic endothelial cells (HAEC). Both paraquat and L-Hcy induced elevated  $O_2^{-1}$  levels that paralleled cell death and which were prevented by pretreating the cells with CNCbl before the insult. Elevated  $O_2^{-1}$  levels were also observed in cells treated with the Cu/Zn-SOD inhibitor diethyldithiocarbamate (DETC) [27] and were similarly attenuated by CNCbl pretreatment.

#### Materials and methods

#### Synthesis of L- and D-Hcy

L- or D-Homocysteine thiolactone (20 mg, 130  $\mu$ mol) was dissolved in NaOH (5 N, 200  $\mu$ ) and incubated at 37 °C for 10 min. The solution was chilled and neutralized with HCl (5 N, 200  $\mu$ ). PBS was added to a total volume of 1 ml and the solution bubbled with N<sub>2</sub> for 10 min [28]. The yield was typically >95%, determined by quantifying the reduced thiol groups by the Ellman assay [29].

#### Cell culture

Primary HAEC clones were a generous gift from Donald W. Jacobsen (Lerner Research Institute, The Cleveland Clinic). Each endothelial cell isolate was stored and passaged separately. HAEC were cultured in fibronectin-coated flasks in M199 supplemented with Lonza Bullet kit supplements for EBM-2 Endothelial Basal Medium in a humidified 95% air, 5% CO<sub>2</sub> incubator at 37 °C. For experiments cells were seeded onto 96- or 6-well plates at a density of 12,000–20,000 cells/cm<sup>2</sup> and used up to passage 6.

#### Intracellular Cbl content and Cbl uptake

For Cbl-uptake experiments, preconfluent HAEC were incubated with 0.2 nM <sup>57</sup>Co-CNCbl. Adherent cells were harvested at various time points up to 24 h and thoroughly washed with PBS. The intracellular Cbl uptake was determined by counting the cell-associated radioactivity. To measure total intracellular Cbl content, preconfluent HAEC were incubated with or without varying concentrations of CNCbl for 24 h, and intracellular Cbl content was determined by the SimulTRAC radioassay.

#### Assessing ROS production

Cells with or without CNCbl pretreatment (500 pM–10  $\mu$ M) were incubated with L-Hcy (100 or 150  $\mu$ M), H<sub>2</sub>O<sub>2</sub> (50–200  $\mu$ M), paraquat (1.5 mM), rotenone (5  $\mu$ M), or culture medium alone. To assess general ROS production, cells were incubated with the oxidation-sensitive fluorescent probe dichlorofluorescein acetate (DCFA; 3  $\mu$ M)

for the duration of the L-Hcy or H<sub>2</sub>O<sub>2</sub> treatment. For the assessment of O<sub>2</sub><sup>-</sup> production, cells were incubated with the oxidative fluorescent probes dihydroethidium (DHE, 5  $\mu$ M) or MitoSOX (5  $\mu$ M) for 1 h subsequent to the L-Hcy, paraquat, or rotenone treatment. Fluorescence was quantified in a microplate reader (dichlorofluorescein (DCF),  $\lambda_{ex/em} = 420/520$ ; 2-hydroxyethidium,  $\lambda_{ex/em} = 510/605$  nm; MitoSOX,  $\lambda_{ex/em} = 510/580$  nm).

#### Cell viability

Cell viability was assessed with trypan blue staining or with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For the MTT assay cells were incubated with thiazolyl blue tetrazolium (0.4 mg/ml) in M199 for 3 h at 37 °C. Mitochondrialdependent tetrazolium reduction to formazan was measured by reading optical density at 540 nm.

## Cbl protection against $O_2^{\star-}$ -generating insult $\mbox{\tiny L-Hcy},$ paraquat, or rotenone

Preconfluent HAEC were incubated for 24 h in the absence or presence of CNCbl (500 pM–10  $\mu$ M) before addition of L-Hcy (100 or 150  $\mu$ M), paraquat (1.5 mM), or rotenone (5  $\mu$ M). For some experiments SOD (3  $\mu$ M) was added at the time of paraquat addition or apocynin (0.1 mM) was added 30 min before adding L-Hcy or paraquat. Cells were incubated for 24 h with L-Hcy, H<sub>2</sub>O<sub>2</sub>, or paraquat or for 1 h with rotenone. ROS and cell viability were assessed as described above.

#### DETC

Pre-confluent HAEC were incubated for 24 h in the absence or presence of CNCbl and then subjected to 10 mM DETC for 2 h. This concentration has been previously shown to inhibit Cu/Zn-SOD activity by up to 50% and to increase vascular  $O_2^-$ [30].

#### DNA and Cbl quantification

Confluent cells were harvested in lysis buffer (50 mM Tris, pH 7.4, 0.5% Triton X-100) and DNA was quantified using the CyQuant cell proliferation kit (Roche). Cbl was quantified using the SimulTRAC radioassay for vitamin  $B_{12}$  and folate by MP Biomedicals (Orangeburg, NY, USA) according to the manufacturer's specifications.

#### Apoptosis measurement

To detect apoptotic cell death, cells were seeded onto six-well plates and pretreated with or without CNCbl (10–100 nM) for 24 h. Cells were washed and then incubated in the absence or presence of L-Hcy for 18 h. Apoptosis was assessed using the Cell Death Detection ELISA (Roche) according to the manufacturer's specifications.

#### *General solution preparation*

Thiol solutions were prepared immediately before use and the concentrations were determined by the Ellman method [29]. A fresh solution of  $H_2O_2$  was prepared before experiments and the concentration determined spectrophotometrically ( $\epsilon_{240 \text{ nm}} = 43.6 \text{ M}^{-1} \text{ cm}^{-1}$  [31]). The concentration of the stock solution of CNCbl was determined by the dicyanocobalamin test ( $\epsilon_{368 \text{ nm}} = 30.4 \text{ mM}^{-1} \text{ cm}^{-1}$ [32]).

#### Statistics

All experiments were carried out using at least three separate cell clones. Results are expressed as means  $\pm$  SEM. Statistical comparisons were carried out using ANOVA with the Bonferroni post hoc test.

#### Results

#### Cbl protects against elevated $O_2^{\bullet-}$ levels induced by Hcy exposure

Treatment of HAEC with varying concentrations of L-Hcy induced a concentration-dependent increase in ROS detected by increasing DCF fluorescence, a general probe for ROS. L-Hcy (100  $\mu$ M) elicited a significant increase in ROS compared to control (Fig. 1). To verify that the ROS increase was an L-Hcy-specific effect, HAEC were incubated for 48 h with a range of thiols (glutathione, L-cysteine, D-Hcy, L-Hcy, and  $\beta$ -mercaptoethanol ( $\beta$ ME)) at 0.1 mM. Only L-Hcy elicited a significant increase in DCF fluorescence (Supplementary Fig. S1A), concomitant with a significant decrease in cell viability as measured using the MTT assay (Fig. S1B).

Before determining the effect of vitamin  $B_{12}$  (CNCbl) on L-Hcydependent ROS levels, we assessed the concentration- and timedependent uptake of CNCbl by HAEC. Incubating HAEC with <sup>57</sup>Co-labeled CNCbl (0.2 nM) induced a time-dependent increase in intracellular CNCbl (Fig. 2A). Increasing the CNCbl in the medium (0.1–10  $\mu$ M unlabeled Cbl) led to higher intracellular Cbl levels after 24 h (Fig. 2B). A 24-h incubation time with CNCbl was selected as an appropriate time for all subsequent experiments.

Exposing HAEC to L-Hcy (150 µM) over 48 h induced a 1.25-fold increase in DCF fluorescence (Fig. 3A) that correlated with an ~25% decrease in cell viability (Fig. 3B). To assess the effects of CNCbl on the L-Hcy-dependent ROS production and the L-Hcy-dependent decrease in cell viability, HAEC were preincubated with increasing concentrations of CNCbl for 24 h before the cells were treated with L-Hcy (150 µM). To ensure that extracellular Cbl was not responsible for the Cbl effects on ROS, the cells were washed after Cbl treatment and the medium was replaced before further treatments. Preincubation of HAEC with CNCbl prevented the L-Hcy-dependent increase in ROS and decrease in cell viability in a concentration-dependent fashion (Fig. 3). CNCbl at 10 nM completely inhibited both the L-Hcy-dependent ROS increase (p < 0.05) and the L-Hcy-dependent decrease in cell viability (p < 0.05). L-Hcy (150 µM) treatment of cells over a 24-h period resulted in an ~20% decrease in cell viability; hence, subsequent experiments were conducted using a 24-h L-Hcy treatment protocol, unless otherwise stated.

Exposing cells to L-Hcy is reported to increase intracellular  $O_2^-$  levels [21,22]. To determine if  $O_2^-$  is indeed generated in our system,  $O_2^-$  levels after exposure to L-Hcy were assessed using the  $O_2^-$ -specific probe DHE, which upon reacting with  $O_2^-$  yields the fluorescent product 2-hydroxyethidium. Incubation of HAEC with L-Hcy (150  $\mu$ M) for 24 h



**Fig. 1.** L-Hcy-induced ROS increase. Preconfluent HAEC were incubated with increasing concentrations of L-Hcy in the presence of 3  $\mu$ M DCFA. After 48 h ROS production was assessed fluorimetrically. Positive control was exposed to 200  $\mu$ M H<sub>2</sub>O<sub>2</sub> ( $\blacklozenge$ ). Data are expressed as the mean  $\pm$  SEM; N = 3. \*p < 0.05 compared to control cells not exposed to L-Hcy.



**Fig. 2.** Effect of exogenous CNCbl on intracellular Cbl content. (A) Preconfluent HAEC were incubated with 0.2 nM <sup>57</sup>Co-CNCbl for up to 24 h and then harvested at various time points. The intracellular Cbl uptake was determined by counting the cell-associated radioactivity. Data represent the mean  $\pm$  SEM; N = 3. (B) Preconfluent HAEC were incubated with or without varying concentrations of CNCbl for 24 h, and intracellular Cbl content was determined by the SimulTRAC radioassay. Data represent the mean  $\pm$  SEM; N = 3.

induced a 1.6-fold increase in hydroxyethidium fluorescence (Fig. 4 and Supplementary Fig. S2). This increase was completely inhibited by preincubation of the cells with 10 nM CNCbl (p<0.05), the antioxidant apocynin (0.1 mM), or SOD itself (3  $\mu$ M) (Fig. 4 and Supplementary Figs. S2 and S3).

#### *Cbl* protects against elevated mitochondrial $O_2^{\bullet-}$ levels

To investigate the subcellular localization of the L-Hcy-induced increase in  $O_2^{-}$ , cells were assayed with MitoSOX, a mitochondrial-specific  $O_2^{-}$  probe. Incubation of HAEC with L-Hcy (150  $\mu$ M) for 24 h elicited a moderate but significant increase in MitoSOX fluorescence, which was completely inhibited by preincubation of the cells with CNCbl (50 nM) (Fig. 5). Moreover, treatment of HAEC with the mitochondrial electron transport chain inhibitor rotenone (5  $\mu$ M) induced an increase in mitochondrial  $O_2^{-}$  that was also significantly inhibited by preincubation with CNCbl (100 nM) (Fig. 5 and Supplementary Fig. S4).

#### Cbl protects against elevated $O_2^{\bullet-}$ levels induced by paraquat

To assess the ability of CNCbl to protect against a direct source of  $O_2^-$ , HAEC were exposed to paraquat (1.5 mM, 24 h), a well-established  $O_2^$ source [33]. Paraquat induced a 1.5-fold increase in  $O_2^-$  production measured by hydroxyethidium fluorescence, which was prevented by



**Fig. 3.** Cbl protection against L-Hcy-induced oxidative stress. Preconfluent HAEC were incubated with increasing concentrations of CNCbl for 24 h before the addition of 150  $\mu$ M L-Hcy. ROS were measured by detecting oxidation of 3  $\mu$ M DCFA. (A) ROS fold increase after 48 h. (B) Cell viability after 48 h as measured with MTT assay. Data are expressed as the mean  $\pm$  SEM; N = 7; \*p < 0.05 with respect to control cells not exposed to L-Hcy; \*p < 0.05 with respect to CNCbl.



**Fig. 4.** Cbl protection against L-Hcy induced superoxide production. Preconfluent HAEC were incubated in the absence or in the presence of 10 or 50 nM CNCbl for 24 h. The cells were washed with PBS before incubation with 150  $\mu$ M L-Hcy with or without 0.1 mM apocynin or 3  $\mu$ M SOD. Hydroxyethidium fluorescence was measured with a fluorescence plate reader after 24 h. Data are expressed as the mean  $\pm$  SEM; N = 6 except for the SOD experiment, for which N = 3. \*p < 0.05 with respect to L-Hcy-treated cells.

CNCbl pretreatment (10 nM), apocynin (0.1 mM), and SOD (3  $\mu$ M) (Fig. 6A). The paraquat-induced increase in oxidative stress correlated with a 30% decrease in cell viability (Fig. 6B). Preincubation with CNCbl for 24 h or treatment with apocynin (0.1 mM) or SOD (3  $\mu$ M) protected HAEC against the O<sub>2</sub><sup>--</sup>-dependent decrease in cell viability (Fig. 6B).

#### *Cbl* attenuates elevated $O_2^{\bullet-}$ levels resulting from *Cu/Zn-SOD* inhibition

To explore the possibility that Cbl can act as a second line of defense when  $O_2^{-}$  production overwhelms the SOD capacity, we inhibited Cu/Zn-SOD by treating HAEC with DETC (10 mM) for 2 h with or without CNCbl pretreatment. Incubation with DETC elicited an increase in DHE fluorescence indicative of higher intracellular  $O_2^{-}$  levels. Pretreatment with CNCbl (100 nM) significantly reduced the DETC-induced DHE fluorescence (Fig. 7), providing support for CNCbl's ability to scavenge  $O_2^{-}$  in SOD-compromised cells.

#### Cbl protects against Hcy-dependent increase in apoptotic cell death

Exposing HAEC to L-Hcy (150  $\mu$ M) for 24 h caused a significant decrease in cell viability as measured by the MTT assay (Fig. 8A). Because the MTT assay is a measure of mitochondrial function and metabolic activity, cell death was directly assessed by trypan blue staining, which corresponded to the MTT results (Fig. 8B). Finally, to characterize the L-Hcy-induced cell death, apoptosis was assessed by measuring cytosolic fragmented DNA with an ELISA-based cell death assay (Roche). HAEC showed a significant increase in apoptotic cell death in response to L-Hcy (150  $\mu$ M) for 18 h (Fig. 9). Because both CNCbl and apocynin prevented the L-Hcy-induced decrease in cell viability, as measured by trypan blue staining (Fig. 8A), and the increase in cell death, as measured by trypan blue staining (Fig. 8B) or ELISA (Fig. 9), it appears that CNCbl provides protection against apoptosis.

#### Discussion

Vitamin  $B_{12}$  is an essential micronutrient required for one-carbon metabolism and branched-amino-acid catabolism. Recent studies in our laboratories showed that Cbl(II) can directly scavenge  $O_2^{-1}$  to form aquacobalamin (and hydrogen peroxide) extremely rapidly, at a rate approaching that of SOD-catalyzed dismutation  $(7 \times 10^8 \text{ vs} 2 \times 10^9 \text{ M}^{-1} \text{ s}^{-1})$  [6]. Substantial free (non-protein-bound)



**Fig. 5.** Subcellular localization of Hcy-induced oxidative stress. HAEC were incubated in the absence or in the presence of CNCbl (50 or 100 nM) for 24 h. The HAEC were washed and exposed to L-Hcy (150  $\mu$ M, 24 h) or rotenone (5  $\mu$ M, 1 h). Mitochondrial  $O_2^-$  was detected by quantifying MitoSOX fluorescence in a microplate reader ( $\lambda_{ex/em} = 510/580$  nm). Data are expressed as the mean  $\pm$  SEM;  $N \ge 4$ ; \*p < 0.05 compared to control, \*p < 0.05.





**Fig. 6.** Effect of Cbl on paraquat-induced O<sub>2</sub><sup>-</sup> levels and cell death. HAEC were incubated in the absence or in the presence of varying concentrations of CNCbl for 24 h before paraquat (1.5 mM) treatment. DHE (5 µM) was added for the final 1 h of treatment. Also shown are the effects of SOD (3 µM) and apocynin (AC; 0.1 mM) on the paraquatinduced increase in O<sub>2</sub><sup>-</sup> and cell death. (A) O<sub>2</sub><sup>-</sup> measured as hydroxyethidium fluorescence ( $\lambda_{ex/em} = 520/605$  nm) compared to untreated cells. (B) Cell viability was assessed with the MTT assay. Data expressed as the mean ± SEM; *N*=3; \**p*<0.05 compared to control, \**p*<0.05 compared to paraquat alone.



**Fig. 7.** Cbl attenuates the DETC-induced increase in superoxide levels. Preconfluent HAEC were incubated in the absence or in the presence of 100 or 500 nM CNCbl for 24 h. Cells were washed with PBS before incubation with 10 mM DETC. After 2 h, the cells were incubated with 5  $\mu$ M DHE for 1 h. Hydroxyethidium fluorescence was measured with a fluorescence plate reader. Data are expressed as the mean  $\pm$  SEM; N = 5. \*p < 0.05 with respect to untreated HAEC; \*p < 0.05 with respect to DETC alone.

**Fig. 8.** Cbl protection against L-Hcy-induced cell death. Preconfluent HAEC were incubated in the presence or absence of 10 or 50 nM CNCbl for 24 h before addition of 150  $\mu$ M L-Hcy for 24 h in the presence or absence of apocynin (0.1 mM). (A) Cell viability by the MTT assay. Data are expressed as the mean  $\pm$  SEM; N = 4. (B) Trypan blue uptake. Data are expressed as the mean  $\pm$  SEM; N = 3. \*p<0.05 with respect to control cells not exposed to L-Hcy; \*p<0.05 with respect to L-Hcy-treated HAEC.

intracellular Cbl can be achieved with supplementation [36–39]. Upon entering cells the cobalt(III) center of Cbl is reduced to cobalt(II) (= Cbl (II)) before binding to the B<sub>12</sub>-dependent enzymes [40]. The ability of cells to re-reduce free aquacobalamin to Cbl(II) ("aquacobalamin reductase activity") is well established [41–46], therefore providing the theoretical basis for Cbl-mediated catalytic O<sub>2</sub><sup>--</sup> scavenging. This led us to speculate that Cbl might protect cells from oxidative stress by efficient O<sub>2</sub><sup>--</sup> scavenging.

In our studies, intracellular  $O_2^{-}$  was generated by treating HAEC with paraquat, and the ability of CNCbl to protect cells against damage was assessed. CNCbl at nanomolar concentrations could prevent the increase in  $O_2^{-}$  levels and the associated reduction in cell viability (Fig. 6). The inhibitory effects of CNCbl were comparable to those observed with apocynin or SOD itself (Fig. 6).

The inhibition of Cu/Zn-SOD with DETC treatment also elevated cytosolic  $O_2^{-}$  levels. DETC-treated cells were round and loosely attached compared to spindle-shaped control cells, demonstrating the dramatic effect of inhibiting Cu/Zn-SOD in HAEC. Pretreating HAEC with CNCbl (100 nM) attenuated the DETC-induced increase in  $O_2^{-}$  and also partially reverted the altered cell morphology, which further supports the direct effect of Cbl on intracellular  $O_2^{-}$ .



**Fig. 9.** Cbl protection against L-Hcy-induced apoptosis. Preconfluent HAEC were incubated in the presence or absence of varying concentrations of CNCbl for 24 h before being exposed to 150  $\mu$ M L-Hcy in the presence or absence of apocynin (0.1 mM). Shown also are corresponding data for apocynin and apocynin + CNCbl. Apoptotic DNA fragmentation was measured by ELISA. Data are expressed as the mean  $\pm$  SEM; N = 4;  $^{*}p$  < 0.05 with respect to control;  $^{\#}p$  < 0.05 with respect to L-Hcy-treated HAEC.

Additionally, CNCbl could blunt the generation of  $O_2^{-1}$  by Hcy. Hcy has been shown to induce an increase in intracellular  $O_2^{-1}$  levels [21,22]. Moreover, elevated Hcy is associated with vascular oxidative stress. Normally, plasma Hcy levels are maintained below 12  $\mu$ M; however, in clinical hyperhomocysteinemia, Hcy levels can exceed 100  $\mu$ M in severe instances [47]. To ensure a universal response among our individual HAEC clones, our experiments used a high but still pathophysiological range of Hcy concentrations (100–150  $\mu$ M), which increased  $O_2^{-1}$  levels and resulted in an associated loss of cell viability. As with paraquat, these effects were completely inhibited by pretreating HAEC with CNCbl (10 nM) or by treating the cells with apocynin or SOD itself.

The increase in L-Hcy-induced cell death correlated with increased apoptotic cell death. L-Hcy induces apoptosis in human bone marrow stromal cells [48], human umbilical vein endothelial cells [49,50], and endothelial progenitor cells [51]. It also inhibits growth [52] and reduces cell viability in HAEC [53]. Our results are consistent with previous studies in other endothelial cell lines; however, to our knowledge, we are the first to show L-Hcy induced apoptotic cell death in primary cultures of HAEC. L-Hcy-induced apoptosis was prevented by apocynin or by pretreating HAEC with CNCbl (50 nM).

The protective effects of Cbl against L-Hcy-induced oxidative stress are perhaps not surprising, given the cofactor role of Cbl in Hcy metabolism. However, our experiments indicate that Cbl shows effects against  $O_2^-$  generated in response to a variety of insults apart from Hcy (i.e., paraquat, rotenone, DETC). Such results indicate that Cbl protection against Hcy-mediated oxidative stress may not be due to increasing Hcy metabolism alone and that Cbl can act to protect against oxidative stress in a general manner. These data, combined with our previous in vitro studies showing a direct and fast reaction between Cbl(II) and  $O_2^-$ , strongly implicate Cbl as an intracellular  $O_2^-$  scavenger. However, in the case of Hcy, we cannot rule out the involvement of other mechanisms independent of  $O_2^-$  scavenging in the CNCbl-mediated protective effects.

An important finding from our studies is the effectiveness of CNCbl against mitochondrial oxidative stress. Oxidative stress-associated mitochondrial dysfunction is a common feature in cardiovascular pathologies [54,55] and there is considerable interest in developing mitochondrial-specific antioxidants [55,56]. Hcy increases mitochondrial oxidative stress in brain [57] and cardiac myocytes [58]. Cbl is present in the mitochondrial (Cbl-dependent L-methylmalonyl-CoA mutase is a mitochondrial enzyme) and ~80% of Cbl is in its Cbl(II)

form [2]. In endothelial cells the mitochondrial AdoCbl concentration is fourfold higher than the cytosolic MeCbl concentration [59] and a substantial fraction of mitochondrial Cbl is not protein bound [60]. In our studies, CNCbl treatment effectively inhibited the generation of mitochondrial  $O_2^{-}$  by Hcy or rotenone treatment (Fig. 5).

DHE remains one of the most widely used probes for detection of O<sub>2</sub><sup>--</sup> in live cells, although 2-hydroxyethidium, the specific reaction product between DHE and  $O_2^{\bullet-}$ , is not the only DHE fluorescent oxidation product. Ethidium, a one-electron oxidation product of DHE, has an emission spectrum with a 45% overlap with that of 2-hydroxyethidium [61]. The same applies for the mitochondria-targeted ethidium derivative MitoSOX and its oxidation products [61]. Therefore, the specificity of DHE for detecting  $O_2^{\bullet-}$  levels has been questioned. However, our conclusions are not solely based on the effect of Cbl on DHE or MitoSOX oxidation. The oxidative-stress-inducing insults used in our studies have been shown to increase  $O_2^{\bullet-}$  levels in previous studies using lucigenin chemiluminescence or EPR [21,22,30,62,63], and these data correlate well with an increase in DHE-derived fluorescence. Thus, because  $O_2^{\bullet-}$  is the predominant ROS produced in these systems, the Cbl effect was mimicked by SOD, and our previous studies show that Cbl reacts very rapidly with O<sub>2</sub><sup>•-</sup>, we conclude that the Cbl-dependent decrease in DHE fluorescence is due to a direct Cbl-mediated  $O_2^{\bullet-}$ scavenging mechanism.

It is likely that Cbl has biological roles beyond its ability to act as a cofactor for the two mammalian  $B_{12}$ -dependent enzyme reactions (reviewed by Solomon [19]). Cbl supplementation can be beneficial in treating a range of inflammatory and viral-based diseases associated with oxidative stress [10–16] and also modulates the immune response [64,65]. Moreover, high doses of Cbl have been used to treat pernicious anemia for decades with no apparent toxicity [66]. Cbl therapy normalizes levels of TNF- $\alpha$  and epidermal growth factor in Cbl-deficient patients [64], by a mechanism(s) that is currently unclear. Thus, there are intriguing clinical implications for our observed association between Cbl and intracellular  $O_2^-$  levels. Our results support the hypothesis that Cbl can act as a second line of defense when  $O_2^-$  production overwhelms the SOD protection system. This perhaps accounts for significantly increased oxidative damage markers in patients with inherited disorders of intracellular Cbl metabolism [67].

Our data show that physiologically relevant concentrations (up to  $10^{-7}$  M are achievable in plasma [34,35]) of CNCbl (the common form of Cbl in vitamin supplements) effectively protect against increased intracellular levels of  $O_2^{-}$ , both in the cytosol and in the mitochondria, resulting in a concomitant reduction in cell death. Importantly, these effects were found to be independent of Hcy metabolism. These results, combined with the in vitro kinetic data demonstrating that Cbl(II) efficiently scavenges  $O_2^{-1}$ [6], suggest that direct scavenging of  $O_2^{-}$  by Cbl is an important mechanism by which Cbl protects against intracellular oxidative stress. Our results have important implications both in regard to the high percentage of the elderly who are  $B_{12}$  deficient and in the treatment of chronic inflammatory diseases associated with oxidative stress. These results encourage further studies with animal models to test the efficacy of Cbl as a  $O_2^{-1}$  scavenger in vivo.

Supplementary materials related to this article can be found online at doi:10.1016/j.freeradbiomed.2011.05.034.

#### Acknowledgments

The authors thank Dr. Donald Jacobsen, The Cleveland Clinic, for providing HAEC and Dr. William Chilian, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, and Dr. Andrew McCaddon, Cardiff School of Medicine, for insightful input. Funding for this work was provided by an American Heart Association predoctoral fellowship (E.S.M.), Kent State University (GSS research grant, E.S.M.), the Ohio Board of Regents (J.Y. and N.E.B.), and the NIH (HL52234 and HL71907 to Donald W. Jacobsen; Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106).

#### References

- Olteanu, H.; Banerjee, R. Redundancy in the pathway for redox regulation of mammalian methionine synthase: reductive activation by the dual flavoprotein, novel reductase 1. J. Biol. Chem. 278:38310–38314; 2003.
- [2] Padovani, D.; Banerjee, R. Assembly and protection of the radical enzyme, methylmalonyl-CoA mutase, by its chaperone. *Biochemistry* 45:9300–9306; 2006.
- [3] Chen, P.; Poddar, R.; Tipa, E. V.; Dibello, P. M.; Moravec, C. D.; Robinson, K.; Green, R.; Kruger, W. D.; Garrow, T. A.; Jacobsen, D. W. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv. Enzyme Regul. 39:93–109; 1999.
- [4] Carmel, R.; Green, R.; Rosenblatt, D. S.; Watkins, D. Update on cobalamin, folate, and homocysteine. *Hematology Am. Soc. Hematol. Educ. Program*62–81; 2003.
- [5] Birch, C. S.; Brasch, N. E.; McCaddon, A.; Williams, J. H. A novel role for vitamin B: cobalamins are intracellular antioxidants in vitro. *Free Radic. Biol. Med.* 47: 184–188; 2009.
- [6] Suarez-Moreira, E.; Yun, J.; Birch, C. S.; Williams, J. H.; McCaddon, A.; Brasch, N. E. Vitamin B(12) and redox homeostasis: cob(II)alamin reacts with superoxide at rates approaching superoxide dismutase (SOD). J. Am. Chem. Soc. 131: 15078–15079; 2009.
- [7] Wolters, M.; Strohle, A.; Hahn, A. Cobalamin: a critical vitamin in the elderly. Prev. Med. 39:1256–1266; 2004.
- [8] Green, R.; Miller, J. W. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population. *Clin. Chem. Lab. Med.* 43:1048–1051; 2005.
- [9] Earnest, C. P.; Wood, K. A.; Church, T. S. Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. J. Am. Coll. Nutr. 22: 400–407; 2003.
- [10] Flynn, M. A.; Irvin, W.; Krause, G. The effect of folate and cobalamin on osteoarthritic hands. J. Am. Coll. Nutr. 13:351–356; 1994.
- [11] Greenberg, S. S.; Xie, J.; Zatarain, J. M.; Kapusta, D. R.; Miller, M. J. Hydroxocobalamin (vitamin B12a) prevents and reverses endotoxin-induced hypotension and mortality in rodents: role of nitric oxide. *J. Pharmacol. Exp. Ther.* 273: 257–265; 1995.
- [12] Crocket, J. A. Cyanocobalamin in asthma. Acta Allergol. 11:261-268; 1957.
- [13] Miller, J. W. Vitamin B12 deficiency, tumor necrosis factor-alpha, and epidermal growth factor: a novel function for vitamin B12? *Nutr. Rev.* 60:142–144; 2002.
- [14] Volkov, I.; Rudoy, I.; Press, Y. Successful treatment of chronic erythema nodosum with vitamin B12. J. Am. Board Fam. Pract. 18:567–569; 2005.
- [15] Wheatley, C. A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock. *Med. Hypotheses* 67:124–142; 2006.
- [16] Yamashiki, M.; Nishimura, A.; Kosaka, Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J. Clin. Lab. Immunol. 37:173–182; 1992.
- [17] Molad, Y.; Rachmilewitz, B.; Sidi, Y.; Pinkhas, J.; Weinberger, A. Serum cobalamin and transcobalamin levels in systemic lupus erythematosus. *Am. J. Med.* 88: 141–144; 1990.
- [18] Remacha, A. F.; Montagud, M.; Cadafalch, J.; Riera, A.; Martino, R.; Gimferrer, E. Vitamin B12 transport proteins in patients with HIV-1 infection and AIDS. *Haematologica* 78:84–88; 1993.
- [19] Solomon, L. R. Disorders of cobalamin (vitamin B12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. *Blood Rev.* 21:113–130; 2007.
- [20] McCord, J. M.; Omar, B. A. Sources of free radicals. Toxicol. Ind. Health 9:23-37; 1993.
- [21] Lang, D.; Kredan, M. B.; Moat, S. J.; Hussain, S. A.; Powell, C. A.; Bellamy, M. F.; Powers, H. J.; Lewis, M. J. Homocysteine-induced inhibition of endotheliumdependent relaxation in rabbit aorta: role for superoxide anions. *Arterioscler. Thromb. Vasc. Biol.* **20**:422–427; 2000.
- [22] Ungvari, Z.; Csiszar, A.; Edwards, J. G.; Kaminski, P. M.; Wolin, M. S.; Kaley, G.; Koller, A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. *Arterioscler. Thromb. Vasc. Biol.* 23:418–424; 2003.
- [23] Buetler, T. M.; Krauskopf, A.; Ruegg, U. T. Role of superoxide as a signaling molecule. *News Physiol. Sci.* 19:120–123; 2004.
- [24] Muscoli, C.; Cuzzocrea, S.; Riley, D. P.; Zweier, J. L.; Thiemermann, C.; Wang, Z. Q.; Salvemini, D. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. *Br. J. Pharmacol.* **140**:445–460; 2003.
- [25] Huang, T. T.; Carlson, E. J.; Raineri, I.; Gillespie, A. M.; Kozy, H.; Epstein, C. J. The use of transgenic and mutant mice to study oxygen free radical metabolism. *Ann. N. Y. Acad. Sci.* 893:95–112; 1999.
- [26] Droge, W. Free radicals in the physiological control of cell function. *Physiol. Rev.* 82:47–95; 2002.
- [27] Iqbal, J.; Whitney, P. Use of cyanide and diethyldithiocarbamate in the assay of superoxide dismutases. *Free Radic. Biol. Med.* **10**:69–77; 1991.
- [28] Barbato, J. C.; Catanescu, O.; Murray, K.; Dibello, P. M.; Jacobsen, D. W. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler. Thromb. Vasc. Biol. 27:49–54; 2007.
- [29] Ellman, G. L. A colorimetric method for determining low concentrations of mercaptans. Arch. Biochem. Biophys. 74:443-450; 1958.
- [30] Munzel, T.; Hink, U.; Yigit, H.; Macharzina, R.; Harrison, D. G.; Mulsch, A. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. *Br. J. Pharmacol.* 127:1224–1230; 1999.

- [31] Hildebrandt, A. G.; Roots, I.; Tjoe, M.; Heinemeyer, G. Hydrogen peroxide in hepatic microsomes. *Methods Enzymol.* 52:342–350; 1978.
- [32] Barker, H. A.; Smyth, R. D.; Weissbach, H.; Munch-Petersen, A.; Toohey, J. I.; Ladd, J. N.; Volcani, B. E.; Wilson, R. M. Assay, purification, and properties of the adenylocobamide coenzyme. J. Biol. Chem. 235:181–190; 1960.
- [33] Day, B. J.; Patel, M.; Calavetta, L.; Chang, L. Y.; Stamler, J. S. A mechanism of paraquat toxicity involving nitric oxide synthase. *Proc. Natl. Acad. Sci. U. S. A.* 96: 12760–12765; 1999.
- [34] Honma, K.; Kohsaka, M.; Fukuda, N.; Morita, N.; Honma, S. Effects of vitamin B12 on plasma melatonin rhythm in humans: increased light sensitivity phaseadvances the circadian clock? *Experientia* 48:716–720; 1992.
- [35] Sombolos, K.; Fragia, T.; Natse, T.; Bartholomatos, G.; Karagianni, A.; Katsaris, G.; Christidou, F.; Bamichas, G.; Stangou, M.; Papagalanis, N. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients. J. Nephrol. 15:671–675; 2002.
- [36] Quadros, E. V.; Jacobsen, D. W. The dynamics of cobalamin utilization in L-1210 mouse leukemia cells: a model of cellular cobalamin metabolism. *Biochim. Biophys. Acta* 1244:395–403; 1995.
- [37] Beedholm-Ebsen, R.; van de Wetering, K.; Hardlei, T.; Nexo, E.; Borst, P.; Moestrup, S. K. Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. *Blood* 115:1632–1639; 2010.
- [38] Dan, N.; Cutler, D. F. Transcytosis and processing of intrinsic factor-cobalamin in Caco-2 cells. J. Biol. Chem. 269:18849–18855; 1994.
- [39] Seetharam, B.; Presti, M.; Frank, B.; Tiruppathi, C.; Alpers, D. H. Intestinal uptake and release of cobalamin complexed with rat intrinsic factor. *Am. J. Physiol.* 248: G326–G331; 1985.
- [40] Banerjee, R.; Gherasim, C.; Padovani, D. The tinker, tailor, soldier in intracellular B12 trafficking. *Curr. Opin. Chem. Biol.* 13:484–491; 2009.
- [41] Fiskerstrand, T.; Riedel, B.; Ueland, P. M.; Seetharam, B.; Pezacka, E. H.; Gulati, S.; Bose, S.; Banerjee, R.; Berge, R. K.; Refsum, H. Disruption of a regulatory system involving cobalamin distribution and function in a methionine-dependent human glioma cell line. J. Biol. Chem. 273:20180–20184; 1998.
- [42] Watanabe, F.; Saido, H.; Yamaji, R.; Miyatake, K.; Isegawa, Y.; Ito, A.; Yubisui, T.; Rosenblatt, D. S.; Nakano, Y. Mitochondrial NADH- or NADPH-linked aquacobalamin reductase activity is low in human skin fibroblasts with defects in synthesis of cobalamin coenzymes. J. Nutr. **126**:2947–2951; 1996.
- [43] Watanabe, F.; Nakano, Y.; Tachikake, N.; Kitaoka, S.; Tamura, Y.; Yamanaka, H.; Haga, S.; Imai, S.; Saido, H. Occurrence and subcellular location of NADH- and NADPH-linked aquacobalamin reductases in human liver. *Int. J. Biochem.* 23: 531–533; 1991.
- [44] Watanabe, F.; Nakano, Y.; Maruno, S.; Tachikake, N.; Tamura, Y.; Kitaoka, S. NADH- and NADPH-linked aquacobalamin reductases occur in both mitochondrial and microsomal membranes of rat liver. *Biochem. Biophys. Res. Commun.* **165**:675–679; 1989.
- [45] Pezacka, E. H. Identification and characterization of two enzymes involved in the intracellular metabolism of cobalamin: cyanocobalamin beta-ligand transferase and microsomal cob(III)alamin reductase. *Biochim. Biophys. Acta Gen. Subj.* **1157**: 167–177; 1993.
- [46] Yamada, K.; Gravel, R. A.; Toraya, T.; Matthews, R. G. Human methionine synthase reductase is a molecular chaperone for human methionine synthase. *Proc. Natl. Acad. Sci. U. S. A.* **103**:9476–9481; 2006.
- [47] Welch, G. N.; Loscalzo, J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338: 1042–1050; 1998.
- [48] Kim, D. J.; Koh, J. M.; Lee, O.; Kim, N. J.; Lee, Y. S.; Kim, Y. S.; Park, J. Y.; Lee, K. U.; Kim, G. S. Homocysteine enhances apoptosis in human bone marrow stromal cells. *Bone* **39**:582–590; 2006.
- [49] Dong, F.; Zhang, X.; Li, S. Y.; Zhang, Z.; Ren, Q.; Culver, B.; Ren, J. Possible involvement of NADPH oxidase and JNK in homocysteine-induced oxidative stress and apoptosis in human umbilical vein endothelial cells. *Cardiovasc. Toxicol.* 5:9–20; 2005.
- [50] Zhang, C.; Cai, Y.; Adachi, M. T.; Oshiro, S.; Aso, T.; Kaufman, R. J.; Kitajima, S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. *J. Biol. Chem.* 276: 35867–35874; 2001.
- [51] Alam, M. M.; Mohammad, A. A.; Shuaib, U.; Wang, C.; Ghani, U.; Schwindt, B.; Todd, K. G.; Shuaib, A. Homocysteine reduces endothelial progenitor cells in stroke patients through apoptosis. J. Cereb. Blood Flow Metab. 29:157–165; 2009.
- [52] Wang, H.; Yoshizumi, M.; Lai, K.; Tsai, J. C.; Perrella, M. A.; Haber, E.; Lee, M. E. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 272:25380–25385; 1997.
- [53] Lin, C. P.; Chen, Y. H.; Chen, J. W.; Leu, H. B.; Liu, T. Z.; Liu, P. L.; Huang, S. L. Cholestin (Monascus purpureus rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor-kappaB activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells. J. Biomed. Sci. 15:183–196; 2008.
- [54] Ballinger, S. W. Mitochondrial dysfunction in cardiovascular disease. Free Radic. Biol. Med. 38:1278–1295; 2005.
- [55] Victor, V. M.; Apostolova, N.; Herance, R.; Hernandez-Mijares, A.; Rocha, M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondriatargeted antioxidants as potential therapy. *Curr. Med. Chem.* 16:4654–4667; 2009.
- [56] Cocheme, H. M.; Kelso, G. F.; James, A. M.; Ross, M. F.; Trnka, J.; Mahendiran, T.; Asin-Cayuela, J.; Blaikie, F. H.; Manas, A. R.; Porteous, C. M.; Adlam, V. J.; Smith, R. A.; Murphy, M. P. Mitochondrial targeting of quinones: therapeutic implications. *Mitochondrion* **7**:S94–S102 Suppl; 2007.
- [57] Baydas, G.; Koz, S. T.; Tuzcu, M.; Etem, E.; Nedzvetsky, V. S. Melatonin inhibits oxidative stress and apoptosis in fetal brains of hyperhomocysteinemic rat dams. *J. Pineal Res.* 43:225–231; 2007.

- [58] Moshal, K. S.; Tipparaju, S. M.; Vacek, T. P.; Kumar, M.; Singh, M.; Frank, I. E.; Patibandla, P. K.; Tyagi, N.; Rai, J.; Metreveli, N.; Rodriguez, W. E.; Tseng, M. T.; Tyagi, S. C. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. *Am. J. Physiol. Heart Circ. Physiol.* **295**: H890–H897; 2008.
- [59] Hannibal, L.; Axhemi, A.; Glushchenko, A. V.; Suarez-Moreira, E.; Brasch, N. E.; Jacobsen, D. W. Accurate assessment and identification of naturally occurring cellular cobalamins. *Clin. Chem. Lab. Med.* **46**:1739–1746; 2008.
- [60] Fenton, W. A.; Ambani, L. M.; Rosenberg, L. E. Uptake of hydroxocobalamin by rat liver mitochondria: binding to a mitochondrial protein. J. Biol. Chem. 251:6616–6623; 1976.
- [61] Robinson, K. M.; Janes, M. S.; Pehar, M.; Monette, J. S.; Ross, M. F.; Hagen, T. M.; Murphy, M. P.; Beckman, J. S. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. *Proc. Natl. Acad. Sci. U. S. A.* **103**:15038–15043; 2006.
- [62] Guzik, T. J.; Olszanecki, R.; Sadowski, J.; Kapelak, B.; Rudzinski, P.; Jopek, A.; Kawczynska, A.; Ryszawa, N.; Loster, J.; Jawien, J.; Czesnikiewicz-Guzik, M.; Channon, K. M.; Korbut, R. Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. *J. Physiol. Pharmacol.* **56**:313–323; 2005.

- [63] Dikalov, S. I.; Kirilyuk, I. A.; Voinov, M.; Grigor'ev, I. A. EPR detection of cellular and mitochondrial superoxide using cyclic hydroxylamines. *Free. Radic. Res.* 45: 417–430; 2011.
- [64] Scalabrino, G.; Veber, D.; Mutti, E. Experimental and clinical evidence of the role of cytokines and growth factors in the pathogenesis of acquired cobalamin-deficient leukoneuropathy. *Brain Res. Rev.* 59:42–54; 2008.
- [65] Tamura, J.; Kubota, K.; Murakami, H.; Sawamura, M.; Matsushima, T.; Tamura, T.; Saitoh, T.; Kurabayshi, H.; Naruse, T. Immunomodulation by vitamin B12: augmentation of CD8<sup>+</sup> T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. *Clin. Exp. Immunol.* **116**: 28–32; 1999.
- [66] Mangiarotti, G.; Canavese, C.; Salomone, M.; Thea, A.; Pacitti, A.; Gaido, M.; Calitri, V.; Pelizza, D.; Canavero, W.; Vercellone, A. Hypervitaminosis B12 in maintenance hemodialysis patients receiving massive supplementation of vitamin B12. *Int. J. Artif. Organs* **9**:417–420; 1986.
- [67] Mc Guire, P. J.; Parikh, A.; Diaz, G. A. Profiling of oxidative stress in patients with inborn errors of metabolism. *Mol. Genet. Metab.* 98:173–180; 2009.